Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Equity Income (2022 - 2024)

Historic Equity Income for Amphastar Pharmaceuticals (AMPH) over the last 3 years, with Q1 2024 value amounting to -$573000.0.

  • Amphastar Pharmaceuticals' Equity Income rose 2700.64% to -$573000.0 in Q1 2024 from the same period last year, while for Dec 2024 it was -$573000.0, marking a year-over-year increase of 7107.52%. This contributed to the annual value of -$573000.0 for FY2024, which is 7107.52% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Equity Income of -$573000.0 as of Q1 2024, which was up 2700.64% from -$505000.0 recorded in Q4 2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Equity Income registered a high of -$57000.0 during Q4 2022, and its lowest value of -$785000.0 during Q1 2023.
  • For the 3-year period, Amphastar Pharmaceuticals' Equity Income averaged around -$414555.6, with its median value being -$390000.0 (2023).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Equity Income crashed by 78596.49% in 2023, and later surged by 2700.64% in 2024.
  • Amphastar Pharmaceuticals' Equity Income (Quarter) stood at -$57000.0 in 2022, then crashed by 785.96% to -$505000.0 in 2023, then dropped by 13.47% to -$573000.0 in 2024.
  • Its Equity Income was -$573000.0 in Q1 2024, compared to -$505000.0 in Q4 2023 and -$390000.0 in Q3 2023.